Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.

Tsukamoto S, Tanaka S, Yamada T, Uneda K, Azushima K, Kinguchi S, Wakui H, Tamura K

Diabetes, obesity & metabolism12 Oct 2023Cited by 17 (Europe PMC)

PMID37828829DOI10.1111/dom.15312PepBankPUB-37828829

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanSystematic reviewEfficacy outcome
In Japanese patients with type 2 diabetes, network meta-analysis showed tirzepatide 15 mg reduced HbA1c more than subcutaneous semaglutide 1.0 mg.
In plain wordsIn Japanese people with type 2 diabetes, tirzepatide lowered HbA1c more than injected semaglutide in an indirect comparison.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c reduction versus subcutaneous semaglutide 1.0 mg
Study
n: not reported in source
Comparator
Subcutaneous semaglutide 1.0 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
Tirzepatide 15 mg showed the most significant reduction in HbA1c levels and BW compared with subcutaneous semaglutide 1.0 mg and oral semaglutide 14 mg (HbA1c: mean difference [95% confidence interval] -0.52 [-0.96; -0.08] and - 1.23 [-1.64; -0.81]; BW: -5.07 [-8.28; -1.86] and -6.84 [-8.97; -4.71], respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) that compared GLP-1RAs or GIP/GLP-1RAs in Japanese patients with T2D were selected.
Report a problemFND-3782882901
02HumanSystematic reviewEfficacy outcome
In Japanese patients with type 2 diabetes, network meta-analysis showed tirzepatide 15 mg reduced HbA1c more than oral semaglutide 14 mg.
In plain wordsIn Japanese people with type 2 diabetes, tirzepatide lowered HbA1c more than oral semaglutide in an indirect comparison.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c reduction versus oral semaglutide 14 mg
Study
n: not reported in source
Comparator
Oral semaglutide 14 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
Tirzepatide 15 mg showed the most significant reduction in HbA1c levels and BW compared with subcutaneous semaglutide 1.0 mg and oral semaglutide 14 mg (HbA1c: mean difference [95% confidence interval] -0.52 [-0.96; -0.08] and - 1.23 [-1.64; -0.81]; BW: -5.07 [-8.28; -1.86] and -6.84 [-8.97; -4.71], respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) that compared GLP-1RAs or GIP/GLP-1RAs in Japanese patients with T2D were selected.
Report a problemFND-3782882902
03HumanSystematic reviewEfficacy outcome
In Japanese patients with type 2 diabetes, network meta-analysis showed tirzepatide 15 mg reduced body weight more than subcutaneous semaglutide 1.0 mg.
In plain wordsIn Japanese people with type 2 diabetes, tirzepatide cut body weight more than injected semaglutide in an indirect comparison.
Peptide
Tirzepatide
Outcome
DecreaseBody weight reduction versus subcutaneous semaglutide 1.0 mg
Study
n: not reported in source
Comparator
Subcutaneous semaglutide 1.0 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
Tirzepatide 15 mg showed the most significant reduction in HbA1c levels and BW compared with subcutaneous semaglutide 1.0 mg and oral semaglutide 14 mg (HbA1c: mean difference [95% confidence interval] -0.52 [-0.96; -0.08] and - 1.23 [-1.64; -0.81]; BW: -5.07 [-8.28; -1.86] and -6.84 [-8.97; -4.71], respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) that compared GLP-1RAs or GIP/GLP-1RAs in Japanese patients with T2D were selected.
Report a problemFND-3782882903
04HumanSystematic reviewEfficacy outcome
In Japanese patients with type 2 diabetes, network meta-analysis showed tirzepatide 15 mg reduced body weight more than oral semaglutide 14 mg.
In plain wordsIn Japanese people with type 2 diabetes, tirzepatide cut body weight more than oral semaglutide in an indirect comparison.
Peptide
Tirzepatide
Outcome
DecreaseBody weight reduction versus oral semaglutide 14 mg
Study
n: not reported in source
Comparator
Oral semaglutide 14 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
Tirzepatide 15 mg showed the most significant reduction in HbA1c levels and BW compared with subcutaneous semaglutide 1.0 mg and oral semaglutide 14 mg (HbA1c: mean difference [95% confidence interval] -0.52 [-0.96; -0.08] and - 1.23 [-1.64; -0.81]; BW: -5.07 [-8.28; -1.86] and -6.84 [-8.97; -4.71], respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) that compared GLP-1RAs or GIP/GLP-1RAs in Japanese patients with T2D were selected.
Report a problemFND-3782882904
05HumanSystematic reviewEfficacy outcome
In Japanese patients with type 2 diabetes, network meta-analysis showed subcutaneous semaglutide reduced HbA1c more than oral semaglutide.
In plain wordsIn Japanese people with type 2 diabetes, injected semaglutide lowered HbA1c more than oral semaglutide in an indirect comparison.
Peptide
Semaglutide
Outcome
DecreaseHbA1c reduction, subcutaneous versus oral semaglutide
Study
n: not reported in source
Comparator
Oral semaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Subcutaneous semaglutide showed a superior reduction in HbA1c compared with oral semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) that compared GLP-1RAs or GIP/GLP-1RAs in Japanese patients with T2D were selected.
Report a problemFND-3782882905
06HumanSystematic reviewEfficacy outcome
In Japanese patients with type 2 diabetes, network meta-analysis showed subcutaneous semaglutide was more effective than conventional GLP-1RAs such as dulaglutide, liraglutide and lixisenatide.
In plain wordsIn Japanese people with type 2 diabetes, injected semaglutide worked better than older GLP-1 drugs in an indirect comparison.
Peptide
Semaglutide
Outcome
Direction not reportedEfficacy of subcutaneous semaglutide versus conventional GLP-1RAs
Study
n: not reported in source
Comparator
Conventional GLP-1RAs (dulaglutide, liraglutide, lixisenatide)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Both subcutaneous and oral semaglutide were more effective than conventional GLP-1RAs, such as dulaglutide, liraglutide and lixisenatide.
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) that compared GLP-1RAs or GIP/GLP-1RAs in Japanese patients with T2D were selected.
Report a problemFND-3782882906
07HumanSystematic reviewEfficacy outcome
In Japanese patients with type 2 diabetes, network meta-analysis showed oral semaglutide was more effective than conventional GLP-1RAs such as dulaglutide, liraglutide and lixisenatide.
In plain wordsIn Japanese people with type 2 diabetes, oral semaglutide worked better than older GLP-1 drugs in an indirect comparison.
Peptide
Semaglutide
Outcome
Direction not reportedEfficacy of oral semaglutide versus conventional GLP-1RAs
Study
n: not reported in source
Comparator
Conventional GLP-1RAs (dulaglutide, liraglutide, lixisenatide)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
Both subcutaneous and oral semaglutide were more effective than conventional GLP-1RAs, such as dulaglutide, liraglutide and lixisenatide.
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) that compared GLP-1RAs or GIP/GLP-1RAs in Japanese patients with T2D were selected.
Report a problemFND-3782882907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 5Current
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 4
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.

Summary

Results from this study7

Version history

Subjects

Publication types

MeSH terms

Keywords